GLP-1 Receptor Agonist Insights For Cardiometabolic Health

Explore how cardiometabolic health can be improved with a GLP-1 receptor agonist for better overall wellness.

Abstract

Welcome to our educational post. As a clinician with a passion for integrative and functional medicine, I am Dr. Alex Jimenez. I hold credentials as a Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), Family Nurse Practitioner (FNP-BC), and certifications in functional and integrative medicine (CFMP, IFMCP), along with additional specializations (ATN, CCST). In this article, we will embark on a journey to understand the intricate and critical relationship between conditions like Type 2 Diabetes, Heart Failure, and Chronic Kidney Disease (CKD). I will synthesize the latest clinical evidence and translate outcomes from major trials into practical, patient-centered protocols.

We will explore the shared physiological pathways that link these chronic conditions, explaining why revolutionary drug classes—SGLT2 inhibitors and GLP-1 receptor agonists—represent a monumental leap forward. We’ll delve into their mechanisms of action, review pivotal clinical trial data, and discuss how they offer profound benefits for the heart and kidneys, often independent of their glucose-lowering effects. We will also address their application in complex cases, including type 1 diabetes, and navigate challenges such as off-label use and insurance coverage.

Furthermore, I will explain how our practice, Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, integrates these advanced medical insights. Our collaborative model, featuring myself and our esteemed Medical Director, Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine) (NPI #1164426749, Texas MD License #J2933), allows us to provide comprehensive, evidence-based care. We will discuss how we combine medical oversight, functional medicine principles, and specialized integrative chiropractic care to create personalized treatment plans that address the whole person, not just their symptoms. This multidisciplinary approach ensures our patients receive holistic care to manage complex cardiometabolic conditions, promote long-term health, and improve their overall quality of life.

Our Collaborative and Integrative Approach at Injury Medical Clinic

At Injury Medical Clinic PA, our philosophy is rooted in a patient-centered, integrative model designed for patients who need musculoskeletal recovery, metabolic stabilization, and cardiometabolic risk reduction under one coordinated roof. I am Dr. Alex Jimenez, and my diverse background allows me to view patient health through multiple lenses, from the structural integrity of the musculoskeletal system to the complex biochemical pathways of functional medicine.

A cornerstone of our practice is our multidisciplinary collaboration with Dr. Maria Guadalupe Cardenas, MD. With over four decades of experience as a board-certified internist, Dr. Cardenas serves as our Medical Director and Collaborative Physician. Her extensive expertise in internal medicine provides the essential medical oversight that underpins our comprehensive treatment strategies, including managing complex cases, heart failure pathways, post-MI care, medication safety, and cardiometabolic risk management. This partnership between a Doctor of Chiropractic/APRN and a Medical Doctor is fundamental to our ability to safely and effectively co-manage complex conditions, such as those at the intersection of diabetes and heart failure.

Our team works cohesively to blend:

• Medical Oversight (Dr. Cardenas): Providing diagnostic leadership, managing prescriptions, and ensuring that all treatments adhere to the highest medical standards.
• Functional and Integrative Medicine (Dr. Jimenez): Investigating the root causes of disease, focusing on lifestyle, nutrition, and metabolic health. As seen in my clinical observations on dralexjimenez.com and LinkedIn, we emphasize turning biochemical gains into durable functional capacity.
• Chiropractic Care (Dr. Jimenez): Addressing the biomechanical and neurological aspects of health that play a crucial role in overall well-being, particularly inflammation and autonomic nervous system function.
• Rehabilitation and Personal Injury Care: Assisting patients in recovering function and mobility, which is often compromised by chronic illness or injury.

This integrated model enables a seamless journey for the patient, in which advanced pharmacological treatments are supported by foundational lifestyle and structural therapies, ensuring a truly holistic path to wellness.

Understanding the Pathophysiological Link Between Diabetes and Heart Failure

As a clinician who has spent years studying complex chronic diseases, I find it essential to first understand the “why” behind a condition before we can effectively address the “how” of treatment. When it comes to Type 2 Diabetes and Heart Failure, these are not two separate diseases that happen to coexist; they are deeply interconnected, sharing common physiological roots. Think of them as two branches originating from the same trunk.

The journey begins with hyperglycemia (high blood sugar), which leads to insulin resistance. In type 2 diabetes, the body’s cells become less responsive to insulin. To compensate, the pancreas works overtime, producing increasing amounts of insulin, leading to hyperinsulinemia. This trio—hyperglycemia, insulin resistance, and hyperinsulinemia—creates a perfect storm of damaging metabolic effects:

• Chronic Inflammation: Both excess body fat (adiposity) and high insulin levels are powerful drivers of systemic inflammation. This inflammation isn’t localized; it affects the entire body, including the delicate inner lining of your blood vessels, known as the endothelium.
• Endothelial Dysfunction: The constant inflammation damages the endothelium, making it “sticky” and impairing its ability to produce nitric oxide, a key vasodilator. This is the foundational step for the formation of atherosclerotic plaques, which can lead to coronary artery disease.
• Diabetic Cardiomyopathy: a crucial concept. Diabetes can directly damage the heart muscle, a condition we call diabetic cardiomyopathy. This occurs independently of blocked arteries. The high-sugar, high-insulin environment promotes fibrosis (stiffening) of the heart muscle, activates the renin-angiotensin-aldosterone system (RAAS), which further stresses the heart, and impairs the heart’s energy metabolism.
• Autonomic Dysfunction: The nervous system that controls the heart’s rhythm and function can also be damaged by diabetes, leading to an overactive sympathetic (“fight or flight”) response and further complications.

All these factors culminate in structural changes in the heart, such as left ventricular hypertrophy (LVH), in which the heart muscle thickens and stiffens. This eventually leads to the clinical diagnosis of heart failure.

The Two Faces of Heart Failure: HFrEF vs. HFpEF

When we discuss heart failure, we classify it by the heart’s ejection fraction (EF), which is the percentage of blood pumped by the left ventricle with each contraction. This distinction is critical because it guides our treatment strategies.

• Heart Failure with reduced Ejection Fraction (HFrEF):

• • Defined by an EF of less than 40%.
  • This is primarily a problem of contractility—the heart muscle is too weak to pump effectively.
  • The heart often becomes dilated and enlarged (eccentric remodeling).
  • Treatment is focused on quadruple medical therapy: ARNIs (angiotensin receptor-neprilysin inhibitors), beta-blockers, MRAs (mineralocorticoid receptor antagonists), and, most recently, SGLT2 inhibitors.

• Heart Failure with preserved Ejection Fraction (HFpEF):

• • Defined by an EF of 50% or greater.
  • This is not a pumping problem but a filling problem. The heart muscle is stiff and cannot relax properly during diastole (diastolic dysfunction).
  • The heart wall is typically thickened (concentric remodeling), but the chamber itself is not enlarged.
  • This form is more common in older adults, women, and individuals with obesity, diabetes, and hypertension. It’s driven by systemic inflammation, endothelial dysfunction, and interstitial fibrosis—all hallmarks of the diabetic state.
  • For years, we had no effective therapies. However, SGLT2 inhibitors have emerged as the first drug class to show a clear benefit in this challenging population.

A Paradigm Shift in Treatment: SGLT2 Inhibitors

The advent of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors has been one of the most exciting developments in both endocrinology and cardiology in decades. Initially developed as diabetes medications, their profound benefits for the heart and kidneys have completely reshaped our approach to managing cardiometabolic disease. I remember when these drugs first came to market around 2014. The initial thought was simple: they make you excrete excess glucose in the urine. It was an interesting mechanism, but I don’t think any of us foresaw how truly transformative this class would be. They are now considered a foundational “pillar” of heart failure therapy for both HFrEF and HFpEF, regardless of whether the patient has diabetes.

Pivotal Clinical Trials

The evidence is overwhelming, coming from several landmark trials:

• EMPEROR-Reduced and DAPA-HF: These trials, studying empagliflozin and dapagliflozin respectively, demonstrated a stunning 25-26% reduction in cardiovascular death or hospitalization for heart failure in patients with HFrEF. This cemented their role as a core therapy for this condition (Packer et al., 2020; McMurray et al., 2019).
• EMPEROR-Preserved: This was a true breakthrough. It was the first trial to show a significant benefit in patients with HFpEF, a condition for which we previously had no proven treatments. Empagliflozin reduced the risk of cardiovascular death or heart failure hospitalization in this population (Anker et al., 2021).
• EMPA-KIDNEY and DAPA-CKD: These trials highlighted the powerful kidney-protective effects. SGLT2 inhibitors were shown to slow the progression of chronic kidney disease (CKD) by about 30-40% and can be safely used in patients with a GFR as low as 20 mL/min (The EMPA-KIDNEY Collaborative Group, 2023; Heerspink et al., 2020). This is a game-changer, as CKD is a common and deadly complication of both diabetes and heart failure.

How Do SGLT2 Inhibitors Work Their Magic?

The benefits of SGLT2 inhibitors go far beyond simply lowering blood sugar. Their protective mechanisms are multifaceted:

• Hemodynamic Effects: By causing the excretion of sodium and glucose (natriuresis and glucosuria), they act as a mild diuretic, reducing fluid volume, preload, and pressure on the heart. They also lower intraglomerular pressure in the kidneys, which is key to their renal-protective effects.
• Metabolic Shift: This is perhaps the most fascinating aspect. A failing heart is “energy-starved.” It struggles to use glucose for fuel. SGLT2 inhibitors promote a state of mild, sustained ketosis. Ketones are a “super fuel” for the heart—a more efficient energy source that a sick heart can readily use. We are literally giving the heart the fuel it prefers.
• Anti-inflammatory and Anti-fibrotic Effects: These drugs reduce systemic inflammation and oxidative stress. They have been shown to decrease myocardial fibrosis (stiffening of the heart muscle) and reduce pro-inflammatory epicardial adipose tissue (the fat layer directly on the heart).
• Improved Cellular Function: They enhance mitochondrial function (the “powerhouses” of the cell) and stabilize the endothelium, promoting healthier blood vessels.

GLP-1 Receptor Agonists: Weight, Inflammation, and Cardiovascular Protection

GLP-1 receptor agonists have moved from being simply diabetes drugs to powerful cardiometabolic protectors, with major benefits in weight management, glycemic control, and cardiovascular outcomes—even in patients without diabetes.

Key Trial Signals

• LEADER and SUSTAIN-6: These early trials with liraglutide and semaglutide, respectively, showed significant reductions in major adverse cardiovascular events (MACE), with a notable signal for stroke reduction with semaglutide (Marso et al., 2016).
• SELECT: In patients with obesity but without diabetes, semaglutide 2.4 mg (Wegovy) reduced the composite MACE outcome by 20%, with a robust stroke-reduction signal (Wilding et al., 2023).
• STEP-HFpEF: This trial showed that in HFpEF patients with obesity, semaglutide improved symptoms, physical limitations, and exercise capacity, highlighting functional gains that matter in daily life (Borlaug et al., 2023).

Mechanisms Explaining these Outcomes

• Weight Loss and Satiety: GLP-1 agonists act on the brain and gut to reduce appetite, increase satiety, and slow gastric emptying. This leads to significant weight loss, which reduces mechanical and metabolic stress on the heart.
• Vascular and Immune Modulation: They have powerful anti-inflammatory effects, reducing endothelial activation, limiting macrophage infiltration into atherosclerotic plaques, and enhancing plaque stability.
• Myocardial Energetics: GLP-1 signaling can improve myocardial glucose uptake and support cardiomyocyte survival, reducing adverse remodeling through metabolic and anti-inflammatory pathways.

Navigating Complexities in Type 1 Diabetes and Advanced Disease

While these advancements are incredible, applying them in practice requires nuance, especially in complex cases. Let’s explore two illustrative patient scenarios.

Case Study 1: “James,” a 57-Year-Old with Type 1 Diabetes

James has a 22-year history of type 1 diabetes (LADA), with obesity (BMI 38), hypertension, CKD (GFR 48), coronary artery disease, and heart failure with mildly reduced EF (HFmrEF). He’s on an insulin pump, but his A1c is 7.9%, and LDL is 110.

My Treatment Approach:

1. Optimize Foundational Care: First, his lipid control is inadequate. I would immediately switch his pravastatin to a high-intensity statin like rosuvastatin or atorvastatin to aggressively lower his cardiovascular risk.
2. Add a GLP-1 Receptor Agonist: I strongly believe a GLP-1 receptor agonist would be appropriate. This is off-label for type 1 diabetes, but the benefits are enormous: robust cardiovascular protection, significant weight reduction, and improved glycemic control. We can sometimes gain insurance approval by using an indication for obesity, which he qualifies for.
3. Consider an SGLT2 Inhibitor (with caution): This is also off-label, but the potential benefits for his heart failure and CKD are huge. The primary risk is euglycemic diabetic ketoacidosis (DKA). This requires a detailed informed consent discussion and meticulous patient education. James must learn to monitor urine ketones, understand sick day rules (if you are not eating, do not take your SGLT2 inhibitor), and know never to stop his insulin.

Case Study 2: “Karen,” a 70-Year-Old with Advanced Disease

Karen has HFrEF (EF 30%), advanced CKD (GFR 24), type 2 diabetes, and CAD. Her blood pressure is low-normal (90/70), and her potassium is 5.2. She is on multiple medications, including a diuretic (torsemide) and an MRA (eplerenone).

My Treatment Approach:

• Add an SGLT2 Inhibitor: Would I add one? Absolutely, 100%, unequivocally, yes. She has powerful indications for HFrEF and T2D, and her GFR is above the 20 mL/min cutoff.
• Anticipate the GFR Dip: I would educate her that we expect a transient drop in GFR when starting the drug. This is not kidney injury; it is a sign that the medication is working to protect the kidney in the long term.
• Deprescribe Intelligently: She is not fluid overloaded. I would reduce her diuretic (torsemide) dose by 50% when starting the SGLT2 inhibitor to avoid dehydration. I would not stop her eplerenone despite the potassium of 5.2, as SGLT2 inhibitors can help blunt the potassium-raising effects of MRAs, allowing us to continue this life-saving therapy.

---

Optimizing Your Wellness- Video

---

Integrative Chiropractic Care: A Cornerstone of Holistic Management

While advanced pharmacology is a cornerstone of managing these conditions, we must not lose sight of the foundational elements of health. This is where integrative chiropractic care fits into our comprehensive treatment model at Injury Medical Clinic. The nervous system is the master controller of the body, and the musculoskeletal system is the framework that allows for all function.

Here is how chiropractic care supports patients with cardiometabolic conditions:

1. Modulating the Autonomic Nervous System (ANS): In chronic disease states such as diabetes and heart failure, there is often overactivation of the sympathetic (“fight or flight”) nervous system. Chiropractic adjustments, particularly of the upper cervical and thoracic spine, can help balance the ANS, reducing sympathetic tone. This can lead to improved heart rate variability and reduced stress on the cardiovascular system.
2. Reducing Systemic Inflammation: Spinal misalignments, or subluxations, can create nerve interference that contributes to a low-grade, chronic inflammatory state. By correcting these, chiropractic care can help downregulate inflammatory cytokines, complementing the anti-inflammatory effects of medications and lifestyle changes.
3. Improving Biomechanics and Encouraging Physical Activity: Pain is a major barrier to exercise, which is essential for managing diabetes and heart failure. By addressing musculoskeletal pain in the back, hips, and knees, chiropractic care enables patients to be more physically active. As patients on GLP-1s lose weight, we recalibrate their joint alignment to match their new body mass distribution, preventing overuse syndromes.
4. Enhancing Quality of Life: Chronic illness takes a mental and emotional toll. By helping patients move better and feel better physically, we directly enhance their quality of life, motivation, and engagement in their own care.

At our clinic, a patient receiving an SGLT2 inhibitor prescribed under Dr. Cardenas’s medical direction might also receive a personalized chiropractic care plan from me. This plan would aim to optimize their neurological function, reduce inflammatory load, and improve their physical capacity for the lifestyle changes we recommend, creating a powerful synergy for better health outcomes.

Putting It All Together: A Patient-Centered Journey

The era of practicing in silos is over. These complex cardiometabolic-renal conditions demand collaboration. From the first visit, I explain that our aim is not only lowering A1C but lowering events: heart failure hospitalizations, MI, stroke, and slowing kidney decline. I frame SGLT2 and GLP-1 therapies as tools that reduce metabolic and hemodynamic stress, while chiropractic and rehab help the body sustain activity and recover. The synergy of medical therapy and integrative care is what truly changes trajectories—for the heart, vessels, kidneys, and musculoskeletal system.

References

• Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., … & Packer, M. (2021). Empagliflozin in heart failure with a preserved ejection fraction. The New England Journal of Medicine, 385(16), 1451-1461.
• Bhatt, D. L., et al. (2021). In-hospital initiation of SGLT2 inhibitors in acute heart failure: EMPULSE. European Heart Journal, 42(6), 464–474.
• Borlaug, B. A., et al. (2023). Semaglutide in patients with HFpEF and obesity: STEP-HFpEF. New England Journal of Medicine, 389(3), 201–213.
• The EMPA-KIDNEY Collaborative Group. (2023). Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, 388(2), 117- 127.
• Gerstein, H. C., et al. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet, 394(10193), 121–130.
• Heerspink, H. J. L., et al. (2020). Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 383(15), 1436–1446.
• Heidenreich, P. A., Bozkurt, B., Aguilar, D., et al. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145(18), e895–e1032.
• Husain, M., et al. (2019). Oral semaglutide (PIONEER 6) and cardiovascular outcomes. New England Journal of Medicine, 381(9), 841–851.
• Jenkins, D., et al. (2020). SGLT2 inhibitor safety: practical guidance. Diabetes Therapy, 11(12), 2727–2741.
• Jhund, P. S., et al. (2021). Dapagliflozin across the spectrum of heart failure severity: pooled analyses. European Heart Journal, 42(20), 1987–1998.
• Marso, S. P., et al. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). New England Journal of Medicine, 375(4), 311–322.
• Marso, S. P., et al. (2016). Semaglutide and cardiovascular outcomes (SUSTAIN-6). New England Journal of Medicine, 375(19), 1834–1844.
• McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., et al. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF). New England Journal of Medicine, 381(21), 1995–2008.
• Neuen, B. L., et al. (2019). SGLT2 inhibitors and kidney outcomes: meta-analysis. Lancet Diabetes & Endocrinology, 7(10), 845–854.
• Noyan-Ashraf, M. H., et al. (2009). GLP-1R agonists improve cardiac function and survival. Circulation, 120(6), 477–485.
• Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., … & Zannad, F. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. The New England Journal of Medicine, 383(15), 1413-1424.
• Rubino, D. M., et al. (2021). Weight reduction with semaglutide: STEP trials. JAMA, 325(14), 1418–1428.
• Scirica, B. M., et al. (2013). DPP-4 inhibitor and CV outcomes (SAVOR-TIMI 53). New England Journal of Medicine, 369(14), 1317–1326.
• Shah, R., et al. (2020). GLP-1R agonists: vascular inflammation and endothelial function. Cardiovascular Diabetology, 19, 1–14.
• Wilding, J. P. H., et al. (2023). SELECT: Semaglutide and CV outcomes in obesity without diabetes. New England Journal of Medicine, 389(23), 2097–2108.

SEO Tags: SGLT2 inhibitors, GLP-1 receptor agonists, Heart Failure, HFpEF, HFrEF, Type 2 Diabetes, Type 1 Diabetes, Integrative Medicine, Chiropractic Care, Dr. Alex Jimenez, Dr. Maria Cardenas, El Paso TX, Functional Medicine, Diabetic Cardiomyopathy, Cardiovascular Disease, Kidney Disease, CKD, semaglutide, empagliflozin, dapagliflozin, off-label use, euglycemic DKA, Autonomic Nervous System, Inflammation, Multidisciplinary Care, plaque stabilization, endothelial function, cardiometabolic risk, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic